ATE397932T1 - Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien - Google Patents
Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmienInfo
- Publication number
- ATE397932T1 ATE397932T1 AT03723907T AT03723907T ATE397932T1 AT E397932 T1 ATE397932 T1 AT E397932T1 AT 03723907 T AT03723907 T AT 03723907T AT 03723907 T AT03723907 T AT 03723907T AT E397932 T1 ATE397932 T1 AT E397932T1
- Authority
- AT
- Austria
- Prior art keywords
- ranolazine
- arrhythmia
- medication
- treatment
- production
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title abstract 2
- 230000006793 arrhythmia Effects 0.000 title abstract 2
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229960000213 ranolazine Drugs 0.000 title 1
- 208000018452 Torsade de pointes Diseases 0.000 abstract 2
- 208000002363 Torsades de Pointes Diseases 0.000 abstract 2
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000031352 familial ventricular tachycardia Diseases 0.000 abstract 1
- 208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
- 206010047302 ventricular tachycardia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37015002P | 2002-04-04 | 2002-04-04 | |
| US40829202P | 2002-09-05 | 2002-09-05 | |
| US42258902P | 2002-10-30 | 2002-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397932T1 true ATE397932T1 (de) | 2008-07-15 |
Family
ID=29255318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03723907T ATE397932T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien |
| AT08004276T ATE470445T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08004276T ATE470445T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030220344A1 (de) |
| EP (3) | EP1490066B1 (de) |
| JP (1) | JP4608217B2 (de) |
| KR (2) | KR20040099395A (de) |
| CN (2) | CN100548300C (de) |
| AT (2) | ATE397932T1 (de) |
| AU (3) | AU2003230810B2 (de) |
| CA (1) | CA2481192C (de) |
| CY (1) | CY1110400T1 (de) |
| DE (2) | DE60332975D1 (de) |
| DK (2) | DK1930007T3 (de) |
| ES (2) | ES2345573T3 (de) |
| IL (1) | IL197406A0 (de) |
| MX (1) | MXPA04009637A (de) |
| NO (1) | NO330953B1 (de) |
| NZ (1) | NZ535610A (de) |
| PT (2) | PT1930007E (de) |
| SI (2) | SI1490066T1 (de) |
| WO (1) | WO2003086401A1 (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| CA2486712C (en) * | 2002-05-21 | 2012-01-03 | Cv Therapeutics, Inc. | Method of treating diabetes |
| WO2005061470A1 (en) * | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| CN101072562A (zh) * | 2004-11-09 | 2007-11-14 | Cv医药有限公司 | 在心力衰竭治疗中雷诺嗪与至少一种（抗）重塑剂联合用于逆转左室重塑 |
| CN101098682A (zh) * | 2005-01-06 | 2008-01-02 | Cv医药有限公司 | 包括雷诺嗪的缓释药物制剂 |
| JP2008540437A (ja) * | 2005-05-03 | 2008-11-20 | ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド | キニーネを含有する制御放出調合剤 |
| EP2101775A1 (de) * | 2006-12-21 | 2009-09-23 | Cv Therapeutics, Inc. | Verringerung von herz-kreislauf-symptomen |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| EP2117550A1 (de) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Verwendung von ranolazin zur behandlung nicht-koronarer mikrovaskulärer erkrankungen |
| JP2010518169A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
| WO2008101008A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2689633A1 (en) * | 2007-05-31 | 2008-12-11 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| EA201070914A1 (ru) * | 2008-02-06 | 2011-04-29 | Гайлид Сайэнсиз, Инк. | Применение ранолазина для лечения боли |
| CA2735653A1 (en) * | 2008-09-04 | 2010-03-11 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| US20100113514A1 (en) * | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2010132696A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
| EP2847158A4 (de) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | Zusammensetzungen und verfahren zur behandlung neuromuskulärer erkrankungen und neurodegenerativer erkrankungen |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| SG11201407319YA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US20150148352A1 (en) * | 2012-08-14 | 2015-05-28 | Cellixbio Private Limited | Compositions and methods for the treatment angina and cardiovascular conditions |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| CA2873029A1 (en) | 2012-09-08 | 2014-03-13 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| KR20160035061A (ko) | 2013-08-01 | 2016-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 긴 qt 증후군을 치료하기 위한 화합물 및 방법 |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
| JP6564868B2 (ja) | 2014-10-27 | 2019-08-21 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩 |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN110845355A (zh) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | 用于治疗炎症和疼痛的组合物和方法 |
| KR101617683B1 (ko) | 2015-01-09 | 2016-05-03 | 연세대학교 산학협력단 | 부정맥 치료제 효과 평가 시스템 및 방법 |
| TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
| WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
| CN116808039A (zh) * | 2023-03-27 | 2023-09-29 | 河南中医药大学第一附属医院 | 青藤碱在制备钾离子、钠离子通道抑制剂中的应用 |
| WO2025010429A1 (en) * | 2023-07-06 | 2025-01-09 | The General Hospital Corporation | Method and apparatus for evaluating cardiac function |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE69033967T2 (de) * | 1989-06-23 | 2002-12-19 | Syntex (U.S.A.) Llc, Palo Alto | Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen |
| JPH03141258A (ja) * | 1989-10-25 | 1991-06-17 | Kowa Co | 新規なピペラジン誘導体 |
| DE69429524T2 (de) * | 1993-09-24 | 2002-08-08 | The University Of British Columbia, Vancouver | Aminocyclohexylester und ihre anwendung |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| CN1227004C (zh) * | 2000-02-18 | 2005-11-16 | Cv治疗公司 | 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂 |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| CN1462191B (zh) * | 2000-05-19 | 2013-07-24 | 埃米林药品公司 | Glp-1用于制备治疗急性冠脉综合征的药物的用途 |
| WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
-
2003
- 2003-04-03 US US10/406,894 patent/US20030220344A1/en not_active Abandoned
- 2003-04-04 CA CA2481192A patent/CA2481192C/en not_active Expired - Fee Related
- 2003-04-04 DE DE60332975T patent/DE60332975D1/de not_active Expired - Lifetime
- 2003-04-04 EP EP03723907A patent/EP1490066B1/de not_active Expired - Lifetime
- 2003-04-04 NZ NZ535610A patent/NZ535610A/en not_active IP Right Cessation
- 2003-04-04 PT PT08004276T patent/PT1930007E/pt unknown
- 2003-04-04 DK DK08004276.5T patent/DK1930007T3/da active
- 2003-04-04 EP EP10002699A patent/EP2198866A1/de not_active Withdrawn
- 2003-04-04 SI SI200331293T patent/SI1490066T1/sl unknown
- 2003-04-04 AU AU2003230810A patent/AU2003230810B2/en not_active Ceased
- 2003-04-04 SI SI200331842T patent/SI1930007T1/sl unknown
- 2003-04-04 DK DK03723907T patent/DK1490066T3/da active
- 2003-04-04 WO PCT/US2003/010434 patent/WO2003086401A1/en not_active Ceased
- 2003-04-04 ES ES08004276T patent/ES2345573T3/es not_active Expired - Lifetime
- 2003-04-04 EP EP08004276A patent/EP1930007B1/de not_active Expired - Lifetime
- 2003-04-04 AT AT03723907T patent/ATE397932T1/de active
- 2003-04-04 KR KR10-2004-7015749A patent/KR20040099395A/ko not_active Ceased
- 2003-04-04 CN CNB038078716A patent/CN100548300C/zh not_active Expired - Fee Related
- 2003-04-04 JP JP2003583420A patent/JP4608217B2/ja not_active Expired - Fee Related
- 2003-04-04 KR KR1020107021063A patent/KR20100119804A/ko not_active Abandoned
- 2003-04-04 PT PT03723907T patent/PT1490066E/pt unknown
- 2003-04-04 ES ES03723907T patent/ES2304507T3/es not_active Expired - Lifetime
- 2003-04-04 MX MXPA04009637A patent/MXPA04009637A/es active IP Right Grant
- 2003-04-04 AT AT08004276T patent/ATE470445T1/de active
- 2003-04-04 CN CN200910171650A patent/CN101843619A/zh active Pending
- 2003-04-04 DE DE60321550T patent/DE60321550D1/de not_active Expired - Lifetime
-
2004
- 2004-11-03 NO NO20044783A patent/NO330953B1/no not_active IP Right Cessation
-
2008
- 2008-09-03 CY CY20081100948T patent/CY1110400T1/el unknown
-
2009
- 2009-03-05 IL IL197406A patent/IL197406A0/en unknown
- 2009-03-17 AU AU2009201065A patent/AU2009201065B2/en not_active Ceased
- 2009-09-09 US US12/556,417 patent/US20100004255A1/en not_active Abandoned
-
2011
- 2011-05-09 AU AU2011202135A patent/AU2011202135A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397932T1 (de) | Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien | |
| ATE517658T1 (de) | Arrythmie-klassifizierung und therapiewahl | |
| DE60010702D1 (de) | Behandlung von titanerz zur herstellung von titandioxidpigmenten | |
| ATE411831T1 (de) | Mehrfach-signalmuster zum filtern von fernfeld-r- zacken | |
| DE69821667D1 (de) | Kardioverter zur Behandlung von Vorhofflattern | |
| EP1803486A3 (de) | Verfahren zum Unterscheiden zwischen ventrikulären und supraventrikulären Arrhythmien | |
| DE69832842D1 (de) | Herzschrittmacher, Defibrillator und/oder Cardioverter zur Verringerung von Vorhofsarrythmien | |
| WO2004062479A3 (en) | Non-invasive heart treatment device | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| NO20011283D0 (no) | Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon | |
| CY1106178T1 (el) | 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν | |
| DE60222745D1 (de) | Verwendung von neurofilamentproteinen zur behandlung von tumoren | |
| DE60323994D1 (de) | Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan | |
| ATE337005T1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
| DE602004024526D1 (de) | Kosmetisches peeling-verfahren unter verwendung von harnstoff | |
| DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| ATE427363T1 (de) | In kanzerísen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| MXPA05011428A (es) | Metodo de tratamiento de fibrilacion atrial o trepidacion auricular. | |
| AU4584100A (en) | Morphinoid compounds | |
| WO2004044144A3 (en) | Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue | |
| DE60202446D1 (de) | Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen | |
| UA85232C2 (ru) | Оксабиспидиновые соединения и их применение в лечении сердечных аритмий | |
| ATE497784T1 (de) | Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen | |
| ATE127118T1 (de) | 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1490066 Country of ref document: EP |